Biotech IV Monitor

ACLX — Arcellx Inc.

Acquired by Gilead Sciences · April 2026
Arcellx Inc. was acquired by Gilead Sciences in April 2026. ACLX no longer trades, so its trials are no longer stock catalysts and are left off the trial calendar. The records below are kept for reference; the programs now belong to Gilead Sciences, and their dates may not have been updated since.

Clinical trial readout dates for Arcellx Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

In progress, no date published

Phase 2 ddCAR
Multiple Myeloma (Earlier lines)
date not published
Ongoing

Companies working on similar indications

Discussion

No messages yet. If you follow ACLX, you can start the conversation.
Contact — questions or corrections about ACLX: dukeupt@gmail.com